Mydecine Innovations Group Inc.

Great read touching on the behind-the-scenes aspects of funding psychedelic research and Dr. Matthew Johnson's groundbreaking work in this field!

Funders at Johns Hopkins Shape The Future of Psychedelic Research - Lucid News Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.

In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (WHO) brief released earlier this month (https://bit.ly/378Lwu8). WHO also pointed out young people and women have been more severely impacted by the pandemic than men.

Additionally, the Federal Trade Commission reported that after decades of declining cigarette sales, 2020 marked the first time in 20 years cigarette sales actually increased in the United States.

The global COVID-19 pandemic forced millions of people to work from home making it easier than ever to take a smoke break. Pair that with the added stress of uncertainty and concerns for the health of loved ones, cigarette sales increased by $8.4 Million dollars in 2020.

Mydecine was founded to address these growing concerns and the lack of innovative treatments for mental health and addictions disorders. Our global team is dedicated to efficiently developing new therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders.

The Mydecine business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy, as well as other novel, non-psychedelic molecules with therapeutic potential.

By collaborating with some of the world’s foremost authorities, Mydecine aims to responsibly fast-track the development of new medicines to provide patients suffering from mental health disorders with safe and more effective treatment options.

Learn more by visiting our website: https://www.mydecine.com/our-approach/ip-drug-development

COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide In the first year of the COVID-19 pandemic, global prevalence of anxiety and depression increased by a massive 25%, according to a scientific brief released by the World Health Organization (WHO) today.

The Federal Trade Commission reported that after decades of declining cigarette sales, 2020 marked the first time in 20 years cigarette sales actually increased in the United States.

The global COVID-19 pandemic forced millions of people to work from home making it easier than ever to take a smoke break. Pair that with the added stress of uncertainty and concerns for the health of loved ones, cigarette sales increased by $8.4 Million dollars in 2020.

Safer more effective smoking cessation treatments are needed now more than ever. As we prepare for our upcoming phase 2b clinical trial, we are optimistic about the potential of psychedelic medicine to help people quit smoking.

Learn more about our clinical trial programs by visiting our website.
https://www.mydecine.com/our-approach/clinical-trials

$MYCO.NE $MYCOF $ONFA.F

We will be launching a phase 2b clinical trial in partnership with Johns Hopkins University led by Dr. Matthew Johnson. Dr. Johnson is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction and risk behavior. The planned study evaluates the administration of MYCO-001 with a structured smoking cessation treatment program in ni****ne dependent individuals.

Learn more about our study design in our blog post, "Can psilocybin help you quit smoking?" https://bit.ly/3sJAovK